Intranasal use of Olopatadine hydrochloride-Mometasone furoate remarkably improves rhinitis symptoms and is a viable therapeutic option for short-term seasonal allergic rhinitis.

The purpose of this study was to examine the safety, effectiveness, and pharmacology of the Olopatadine hydrochloride-Mometasone furoate combination for the management of allergic rhinitis.

The following keywords were used to search the ClinicalTrials.gov and PubMed database: Olopatadine hydrochloride, Mometasone furoate, GSP301, and Mometasone + Olopatadine. Clinical trials, safety, and pharmacology-related articles were evaluated.

Two phase II clinical studies showed substantial improvements in instantaneous total nasal symptom score (iTNSS) and reflective total nasal symptom score (rTNSS) with twice-daily and once-daily intranasal Olopatadine-Mometasone. Twice-daily Olopatadine-Mometasone demonstrated considerable enhancements in rTNSS compared to placebo, Olopatadine monotherapy, and Mometasone monotherapy in two phase III clinical studies.

Olopatadine hydrochloride-Mometasone furoate is beneficial to alleviate rhinitis. For some high-risk patients, active tuberculosis, fungal, bacterial, viral, or parasite illnesses, as well as ocular herpes simplex, caution with use is advised. It might be a viable drug for the initial treatment of moderate-to-severe seasonal allergic rhinitis in patients 12 years of age and older due to its immediate and prolonged onset of effect.